The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts

Robyn Marie Scherber, Holly Lynn Geyer, Amylou C. Dueck, Heidi E. Kosiorek, Guido Finazzi, Riccardo Cavazzina, Arianna Masciulli, Marco Scarano, Alessandro M. Vannucchi, Ruben A. Mesa, Tiziano Barbui

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Current guidelines suggest that polycythemia vera (PV) patients maintain a strict hematocrit less than 45%. However, to date, little is known about the relationship between HCT control and PV- related symptom burden. In this study, PV patient data was analyzed from the CYTO PV trial (n = 224) and the MPN-SAF study cohort (n = 645). No significant differences in symptom burden were seen at the 6 and 12 month follow-up when evaluating prospective hematocrit control in the CYTO PV cohort. Patients in the MPN-SAF cohort with a worst item score of greater than 5/10 on the Myeloproliferative Neoplasm Symptom Total Symptom Score had a significantly lower mean hematocrit (p =.0376). These findings suggest a relationship between traditional aggressive therapy for PV and increased symptom burden with prolonged therapy. Thus, symptom burden should be considered when contemplating the choice of therapy in the second-line setting for PV.

Original languageEnglish (US)
Pages (from-to)1481-1487
Number of pages7
JournalLeukemia and Lymphoma
Volume58
Issue number6
DOIs
StatePublished - Jun 3 2017

    Fingerprint

Keywords

  • Symptom burden
  • phlebotomy
  • polycythemia vera
  • quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Scherber, R. M., Geyer, H. L., Dueck, A. C., Kosiorek, H. E., Finazzi, G., Cavazzina, R., Masciulli, A., Scarano, M., Vannucchi, A. M., Mesa, R. A., & Barbui, T. (2017). The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leukemia and Lymphoma, 58(6), 1481-1487. https://doi.org/10.1080/10428194.2016.1246733